Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

DNA test aims to spot hidden gastric cancer spread

NCT ID NCT06308510

Diagnosis Sponsor: Erasmus Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 14, 2026 · Last updated Sep 15, 2026 · Updated 1 time

Summary

Researchers are testing whether measuring aneuploidy (abnormal chromosome numbers) in cell-free DNA from peritoneal lavage fluid can improve the detection of gastric cancer that has spread to the abdominal lining. The study enrolls adults with gastric cancer and non-cancer controls undergoing diagnostic laparoscopy. By comparing this new method to standard cytology and imaging, they hope to find a more sensitive way to stage the disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
collection of additional peritoneal lavage fluid during standard diagnostic laparoscopy
What this could lead to
If the approach works, doctors could detect gastric cancer spread to the abdominal lining earlier and more accurately, which may guide treatment decisions.
What could go wrong
This is a diagnostic accuracy study with 63 participants, so it may not show a clear benefit over standard tests. The technique could miss some cancers or produce false alarms, and results may not apply to all gastric cancer patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 63 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2024

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Gastric cancer patients: Patients who will undergo DLS for GC or GEJ carcinoma Non-cancer controls: Operable patients who will undergo a planned diagnostic laparoscopy for a benign indication (bariatric or gallbladder disease);

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Gastric cancer patients: Inclusion Criteria: * Age ≥18 years old; * Written informed consent according to the ICH-GCP and national/local regula-tions. Exclusion Criteria: \- Language difficulty, dementia or altered mental status prohibiting the under-standing and giving of informed consent. non-cancer controls: Inclusion criteria: * Operable patients who will undergo a planned diagnostic laparoscopy for a benign indication bariatric or gallbladder disease); * Age ≥18 years old; * Written informed consent according to the ICH-GCP and national/local regulations. Exclusion criteria: * Active inflammation or infection; * Subjects with previous malignancies are excluded unless a complete remission was achieved at least 5 years prior to study entry (exceptions include but are not limited to, non-melanoma skin cancers; in situ bladder cancer, or in situ co-lon cancers; in situ cervical cancers/dysplasia; or breast carcinoma in situ).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastric cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

gastric cancer gastric neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gastric cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Erasmus MC

    RECRUITING

    Rotterdam, 3015GD, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.